Authors/year of publication | Country | Male (%) | Mean age | Intervention | Follow-up | Study design | Outcomes assessed | |
---|---|---|---|---|---|---|---|---|
Stem cell | Control | |||||||
Seth/2010 [20] | India | 83.9 | Stem cell: 45 ± 15 years Control: 49 ± 9 years | 41 | 40 | 36 M | RCT | Mortality, LVEF, LVEDCS, and LVESV |
Vrtovec/2011 [14] | USA | 79 | 53 ± 9 years | 28 | 27 | 12 M | RCT | Mortality, LVEF, LVEDCS, and 6-min-walk test |
Vrtovec/2013 [21] | USA | 81 | 54 ± 9 years | 55 | 55 | 60 M | RCT | Mortality, LVEF, LVEDCS, and 6-min-walk test |
Henry/2014 [22] | USA | 68.9 | Stem cell: 57.9 ± 11 years Control: 52.3 ± 11 years | 18 | 11 | 12 M | RCT | Mortality, LVEF, LVESV, and 6-min-walk test |
Sant Anna/2014 [23] | Brazil | 60 | Stem cell: 48.3 ± 8.71 years Control: 51.6 ± 7.79 years | 20 | 10 | 12 M | RCT | Mortality, LVEF, LVESV, LVEDCS, and 6-min-walk test |
Hamshere/2015 [26] | UK | 75.8 | Stem cell: 57.67 ± 12.32 years Control: 56.79 ± 9.84 years | 15 | 14 | 12 M | RCT | Mortality, LVEF, LVEDCS, and LVESV |
Martino/2015 [24] | Brazil | 70.6 | Stem cell: 51 ± 11.1 years Control: 49.6 ± 11.1 years | 82 | 78 | 12 M | RCT | Mortality, LVEF, LVESV, and 6-min-walk test |
Xiao/2017 [25] | China | 75.6 | Stem cell: 51.6 ± 12.2 years Control: 54.4 ± 11.6 years | 17 | 20 | 12 M | RCT | Mortality, LVEF, LVEDCS, and 6-min-walk test |